Related Experiment Videos

CYP3A5 genotype is associated with elevated blood pressure

Martin F Fromm1, Bernhard M W Schmidt, Andreas Pahl

  • 1Institute of Clinical and Experimental Pharmacology and Toxicology, University of Erlangen-Nuremberg, Erlangen, Germany.

Pharmacogenetics and Genomics
|September 6, 2005
PubMed

Insights

The CYP3A5 genotype influences blood pressure in young Caucasian males. Specifically, the CYP3A5*3/*3 genotype is linked to higher systolic blood pressure and lower aldosterone levels.

Area of Science:

  • Pharmacogenomics
  • Cardiovascular Physiology
  • Renal Physiology

Background:

  • CYP3A5 is a key enzyme in the human kidney.
  • Genetic variations in CYP3A5 may impact blood pressure regulation.

Purpose of the Study:

  • To investigate the association between CYP3A5 gene polymorphism and blood pressure in Caucasians.
  • To explore genotype-dependent differences in the renin-angiotensin-aldosterone system.

Main Methods:

  • Recruited 115 young, white male students with untreated normal to mildly elevated blood pressure.
  • Utilized 24-hour ambulatory blood pressure monitoring.
  • Assessed genotype-dependent differences in renin-angiotensin-aldosterone system parameters.

Main Results:

  • Individuals with the CYP3A5*3/*3 genotype exhibited significantly higher 24-hour systolic blood pressure compared to the CYP3A5*1/*3 genotype (129+/-10 vs. 124+/-9 mmHg, P < 0.05).
  • The CYP3A5*3/*3 group showed significantly lower serum aldosterone concentrations (101+/-29 vs. 117+/-29 pg/ml, P < 0.05).
  • No significant associations were found with diastolic blood pressure, angiotensin II levels, renal function, or echocardiographic parameters.

Conclusions:

  • The CYP3A5 genotype appears to influence human blood pressure, potentially through altered renal metabolism of cortisol and/or aldosterone.
  • Lower serum aldosterone in the CYP3A5*3/*3 genotype group may represent a counter-regulatory response to elevated systolic blood pressure.

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...